Anesthesiology:预防性使用氟哌啶醇对谵妄高风险的III级危重患者长期生活质量的影响

2019-08-31 anesthGH 罂粟花

重症监护病房患者谵妄发生率高,且与长期预后受损有关。预防性使用氟哌啶醇并没有改善谵妄高风险的危重患者的短期预后。本研究评估预防性使用氟哌啶醇对这些患者长期生活质量的影响,并探讨哪些因素与生活质量的改变有关。

背景与目的

重症监护病房患者谵妄发生率高,且与长期预后受损有关。预防性使用氟哌啶醇并没有改善谵妄高风险的危重患者的短期预后。本研究评估预防性使用氟哌啶醇对这些患者长期生活质量的影响,并探讨哪些因素与生活质量的改变有关。

方  法

对ICU里谵妄高风险的危重患者预防性使用氟哌啶醇治疗谵妄的远期疗效进行预先计划的二次分析。在这个多中心随机临床试验中,无谵妄的ICU患者分为预防性使用氟哌啶醇组(1或2mg)或安慰剂组(0.9%氯化钠)。两组患者最终接受研究药物治疗的平均时间为3天(四分位范围内,2至6天),直到出现谵妄或从ICU出院。在ICU入院时(基线)和入院后1个月和6个月,采用短表格-12调查表评估长期疗效。生活质量的总结分为身体方面总结和心理方面总结两部分。分析氟哌啶醇组与安慰剂组之间的差异以及与生活质量变化相关的因素。

结 果

共1789名患者,纳入了1245名ICU患者,其中887名(71%)接受了氟哌啶醇治疗。氟哌啶醇组与安慰剂组的长期生活质量无显着差异(身体方面汇总平均得分分别为3911分和3911分,P = 0.350;心理方面总分分别为50分±10分和51分±10分,P = 0.678)。年龄、医疗和创伤入院、基线生活质量评分、谵妄风险(谵妄前)评分、镇静诱导的昏迷天数与长期生活质量下降显着相关。

结 论

预防性使用氟哌啶醇不会影响高风险谵妄的III级危重患者长期生活质量。有几个因素,包括可调整的镇静诱导昏迷天数,与长期预后的下降有关。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916149, encodeId=477b191614927, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 24 17:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862105, encodeId=ad2f1862105ea, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Apr 10 10:49:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051432, encodeId=a18e20514326d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 19 13:49:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034818, encodeId=5d842034818dd, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 27 23:49:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508445, encodeId=6060150844563, content=<a href='/topic/show?id=a4c96391448' target=_blank style='color:#2F92EE;'>#氟哌啶醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63914, encryptionId=a4c96391448, topicName=氟哌啶醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14ae9959934, createdName=venlin, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588386, encodeId=4c291588386ed, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2019-09-24 juliusluan78
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916149, encodeId=477b191614927, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 24 17:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862105, encodeId=ad2f1862105ea, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Apr 10 10:49:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051432, encodeId=a18e20514326d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 19 13:49:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034818, encodeId=5d842034818dd, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 27 23:49:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508445, encodeId=6060150844563, content=<a href='/topic/show?id=a4c96391448' target=_blank style='color:#2F92EE;'>#氟哌啶醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63914, encryptionId=a4c96391448, topicName=氟哌啶醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14ae9959934, createdName=venlin, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588386, encodeId=4c291588386ed, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916149, encodeId=477b191614927, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 24 17:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862105, encodeId=ad2f1862105ea, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Apr 10 10:49:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051432, encodeId=a18e20514326d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 19 13:49:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034818, encodeId=5d842034818dd, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 27 23:49:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508445, encodeId=6060150844563, content=<a href='/topic/show?id=a4c96391448' target=_blank style='color:#2F92EE;'>#氟哌啶醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63914, encryptionId=a4c96391448, topicName=氟哌啶醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14ae9959934, createdName=venlin, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588386, encodeId=4c291588386ed, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2020-01-19 zhouqu_8
  4. [GetPortalCommentsPageByObjectIdResponse(id=1916149, encodeId=477b191614927, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 24 17:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862105, encodeId=ad2f1862105ea, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Apr 10 10:49:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051432, encodeId=a18e20514326d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 19 13:49:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034818, encodeId=5d842034818dd, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 27 23:49:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508445, encodeId=6060150844563, content=<a href='/topic/show?id=a4c96391448' target=_blank style='color:#2F92EE;'>#氟哌啶醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63914, encryptionId=a4c96391448, topicName=氟哌啶醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14ae9959934, createdName=venlin, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588386, encodeId=4c291588386ed, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1916149, encodeId=477b191614927, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 24 17:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862105, encodeId=ad2f1862105ea, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Apr 10 10:49:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051432, encodeId=a18e20514326d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 19 13:49:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034818, encodeId=5d842034818dd, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 27 23:49:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508445, encodeId=6060150844563, content=<a href='/topic/show?id=a4c96391448' target=_blank style='color:#2F92EE;'>#氟哌啶醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63914, encryptionId=a4c96391448, topicName=氟哌啶醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14ae9959934, createdName=venlin, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588386, encodeId=4c291588386ed, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1916149, encodeId=477b191614927, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 24 17:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862105, encodeId=ad2f1862105ea, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Apr 10 10:49:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051432, encodeId=a18e20514326d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 19 13:49:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034818, encodeId=5d842034818dd, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 27 23:49:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508445, encodeId=6060150844563, content=<a href='/topic/show?id=a4c96391448' target=_blank style='color:#2F92EE;'>#氟哌啶醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63914, encryptionId=a4c96391448, topicName=氟哌啶醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14ae9959934, createdName=venlin, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588386, encodeId=4c291588386ed, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Sep 02 07:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2019-09-02 skhzy

相关资讯

JAMA:预防性氟哌啶醇对谵妄高风险危重病患者的疗效

谵妄是一种急性脑病,特征为急性发作的意识模糊,注意力不集中和意识水平变化,这些症状在一天之中波动。ICU中谵妄非常常见,发生率为30-50%。谵妄与临床预后不良有关,包括机械通气时间延长,增加ICU和住院时间,增加死亡率。并且,当谵妄消失后,认知功能损害将持续。

NEJM:氟哌啶醇和齐拉西酮治疗重症疾病患者谵妄的疗效

由此可见,与安慰剂相比,在ICU中急性呼吸衰竭或休克以及低活性或过度活跃的谵妄患者中使用氟哌啶醇或齐拉西酮并未显著改善谵妄的持续时间。

BMJ:氟哌啶醇治疗与急性心肌梗死死亡风险

研究发现,氟哌啶醇治疗导致的急性心肌梗死死亡风险略高于其他非典型抗精神病药物,虽然不能排除混淆因素,但心血管风险高危患者在使用氟哌啶醇时因充分考虑这一潜在风险

ICU中的谵妄和氟哌啶醇:以手指月

氟哌啶醇,合成于60年前的1958年2月,是一种卓越的神经安定剂。诞生以来用于数十万计精神分裂症及其他精神病患者,尤其用于治疗精神病引起的躁动,并被纳入世界卫生组织的基本药物清单。

NEJM:氟哌啶醇和齐拉西酮治疗重症患者谵妄症毫无建树

2018年10月,美国学者在《N Engl J Med》发表的一项研究,考察了氟哌啶醇和齐拉西酮治疗重症患者谵妄症的有效性和安全性。

NEJM:氟哌啶醇不能降低 ICU 患者谵妄持续时间

谵妄是危重病期间急性脑功能障碍的最常见表现,ICU 机械通气患者的发生率为50-75%。谵妄患者的死亡率更高,机械通气和住院时间更长,花费更高,并且往往面临高风险的长期认知功能障碍。谵妄也会妨碍医疗和护理。多动性谵妄(Hyperactive delirium)会意外拔出各种设备,而低活动性谵妄(hypoactive delirium)会不配合护理、物理治疗和职业治疗。